financial results

Pacific Biosciences reported total Q1 2017 revenues of $24.9 million, just beating analysts' average estimate of $24.6 million. 

The company's laboratory services and product revenues both dropped during the quarter.

Illumina's NovaSeq accessory, which it plans to launch in Q4, will enable customers to run different experiments and library types in different flow cell lanes.

The revenue increase was driven by a 41 percent rise in product sales.

The company reported $4.77 billion in first quarter revenues, driven by growth in all of its business segments.

The firm guided second quarter revenues to between $62 million and $64 million and revised its full-year 2017 revenue guidance to between $255 million and $265 million.

The company said that it received orders for 135 of its NovaSeq sequencing instrument in the first quarter 2017.

The company's diagnostics business saw 8 percent growth, while its Covance segment retreated 2 percent. The firm lowered its adjusted EPS estimate for the full year. 

Influenza revenues rose 112 percent due to an especially long and severe respiratory disease season, dominated by a virulent H3N2 strain of influenza.

The company said revenues for the quarter and full-year 2016 included sales of Olerup HLA typing products, which CareDx got through its acquisition of Allenex.

Pages

Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.